Parameter Trajectory Analysis to Identify Treatment Effects of Pharmacological Interventions

The field of medical systems biology aims to advance understanding of molecular mechanisms that drive disease progression and to translate this knowledge into therapies to effectively treat diseases. A challenging task is the investigation of long-term effects of a (pharmacological) treatment, to establish its applicability and to identify potential side effects. We present a new modeling approach, called Analysis of Dynamic Adaptations in Parameter Trajectories (ADAPT), to analyze the long-term effects of a pharmacological intervention. A concept of time-dependent evolution of model parameters is introduced to study the dynamics of molecular adaptations. The progression of these adaptations is predicted by identifying necessary dynamic changes in the model parameters to describe the transition between experimental data obtained during different stages of the treatment. The trajectories provide insight in the affected underlying biological systems and identify the molecular events that should be studied in more detail to unravel the mechanistic basis of treatment outcome. Modulating effects caused by interactions with the proteome and transcriptome levels, which are often less well understood, can be captured by the time-dependent descriptions of the parameters. ADAPT was employed to identify metabolic adaptations induced upon pharmacological activation of the liver X receptor (LXR), a potential drug target to treat or prevent atherosclerosis. The trajectories were investigated to study the cascade of adaptations. This provided a counter-intuitive insight concerning the function of scavenger receptor class B1 (SR-B1), a receptor that facilitates the hepatic uptake of cholesterol. Although activation of LXR promotes cholesterol efflux and -excretion, our computational analysis showed that the hepatic capacity to clear cholesterol was reduced upon prolonged treatment. This prediction was confirmed experimentally by immunoblotting measurements of SR-B1 in hepatic membranes. Next to the identification of potential unwanted side effects, we demonstrate how ADAPT can be used to design new target interventions to prevent these.

[1]  M. Girolami,et al.  Riemann manifold Langevin and Hamiltonian Monte Carlo methods , 2011, Journal of the Royal Statistical Society: Series B (Statistical Methodology).

[2]  Jacob Roll,et al.  Systems biology: model based evaluation and comparison of potential explanations for given biological data , 2009, The FEBS journal.

[3]  William S. Levine,et al.  The Control Handbook , 2005 .

[4]  L Frøyland,et al.  Mitochondrion is the principal target for nutritional and pharmacological control of triglyceride metabolism. , 1997, Journal of lipid research.

[5]  F. Kuhajda,et al.  Fatty acid synthase inhibition in human breast cancer cells leads to malonyl-CoA-induced inhibition of fatty acid oxidation and cytotoxicity. , 2001, Biochemical and biophysical research communications.

[6]  J. Herz,et al.  Role of the low density lipoprotein receptor in the flux of cholesterol through the plasma and across the tissues of the mouse. , 1995, The Journal of clinical investigation.

[7]  D. Mangelsdorf,et al.  LXRs regulate the balance between fat storage and oxidation. , 2005, Cell metabolism.

[8]  Jens Timmer,et al.  Likelihood based observability analysis and confidence intervals for predictions of dynamic models , 2011, BMC Systems Biology.

[9]  F. van der Leij,et al.  Regulatory enzymes of mitochondrial β‐oxidation as targets for treatment of the metabolic syndrome , 2010, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[10]  G. Marsaglia,et al.  Evaluating Kolmogorov's distribution , 2003 .

[11]  Folkert Kuipers,et al.  Stimulation of Lipogenesis by Pharmacological Activation of the Liver X Receptor Leads to Production of Large, Triglyceride-rich Very Low Density Lipoprotein Particles* , 2002, The Journal of Biological Chemistry.

[12]  Ernst Dieter Gilles,et al.  Mathematical modeling and analysis of insulin clearance in vivo , 2008, BMC Systems Biology.

[13]  Gunnar Cedersund,et al.  Conclusions via unique predictions obtained despite unidentifiability – new definitions and a general method , 2012, The FEBS journal.

[14]  Robert Tibshirani,et al.  Bootstrap confidence intervals and bootstrap approximations , 1987 .

[15]  Ben van Ommen,et al.  Improved cholesterol phenotype analysis by a model relating lipoprotein life cycle processes to particle size[S] , 2009, Journal of Lipid Research.

[16]  J. Doyle,et al.  Bow Ties, Metabolism and Disease , 2022 .

[17]  Aldons J. Lusis,et al.  Metabolic syndrome: from epidemiology to systems biology , 2008, Nature Reviews Genetics.

[18]  Kwang-Hyun Cho,et al.  Experimental Design in Systems Biology, Based on Parameter Sensitivity Analysis Using a Monte Carlo Method: A Case Study for the TNFα-Mediated NF-κ B Signal Transduction Pathway , 2003, Simul..

[19]  Zhike Zi,et al.  SBML-SAT: a systems biology markup language (SBML) based sensitivity analysis tool , 2008, BMC Bioinformatics.

[20]  Jacob Roll,et al.  Model-Based Hypothesis Testing of Key Mechanisms in Initial Phase of Insulin Signaling , 2008, PLoS Comput. Biol..

[21]  Graham C. Goodwin,et al.  Estimation of model quality , 1994, Autom..

[22]  Janardan K Reddy,et al.  Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. , 2006, American journal of physiology. Gastrointestinal and liver physiology.

[23]  Michael Q. Zhang,et al.  Network-based global inference of human disease genes , 2008, Molecular systems biology.

[24]  Qinghua Zhang,et al.  Adaptive observer for multiple-input-multiple-output (MIMO) linear time-varying systems , 2002, IEEE Trans. Autom. Control..

[25]  D. Kirschner,et al.  A methodology for performing global uncertainty and sensitivity analysis in systems biology. , 2008, Journal of theoretical biology.

[26]  David Welch,et al.  Approximate Bayesian computation scheme for parameter inference and model selection in dynamical systems , 2009, Journal of The Royal Society Interface.

[27]  Kwang-Hyun Cho,et al.  In silico identification of the key components and steps in IFN‐γ induced JAK‐STAT signaling pathway , 2005, FEBS letters.

[28]  G. Ronnett,et al.  C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[29]  A Kremling,et al.  Exploiting the bootstrap method for quantifying parameter confidence intervals in dynamical systems. , 2006, Metabolic engineering.

[30]  J. Stark,et al.  Systems biology of persistent infection: tuberculosis as a case study , 2008, Nature Reviews Microbiology.

[31]  J. Doyle,et al.  Metabolic syndrome and robustness tradeoffs. , 2004, Diabetes.

[32]  D. Mangelsdorf,et al.  Role of LXRs in control of lipogenesis. , 2000, Genes & development.

[33]  Bassam Bamieh,et al.  Identification of linear parameter varying models , 1999, Proceedings of the 38th IEEE Conference on Decision and Control (Cat. No.99CH36304).

[34]  Jaques Reifman,et al.  A systems biology framework for modeling metabolic enzyme inhibition of Mycobacterium tuberculosis , 2009, BMC Systems Biology.

[35]  Gunnar Cedersund,et al.  Mass and Information Feedbacks through Receptor Endocytosis Govern Insulin Signaling as Revealed Using a Parameter-free Modeling Framework* , 2010, The Journal of Biological Chemistry.

[36]  Pingzhao Hu,et al.  Computational prediction of cancer-gene function , 2007, Nature Reviews Cancer.

[37]  Magda Osman,et al.  Control Systems Engineering , 2010 .

[38]  Gunnar Cedersund,et al.  A Hierarchical Whole-body Modeling Approach Elucidates the Link between in Vitro Insulin Signaling and in Vivo Glucose Homeostasis* , 2011, The Journal of Biological Chemistry.

[39]  Ursula Klingmüller,et al.  Tests for cycling in a signalling pathway , 2004 .

[40]  Ursula Klingmüller,et al.  Structural and practical identifiability analysis of partially observed dynamical models by exploiting the profile likelihood , 2009, Bioinform..

[41]  M. Smit,et al.  Increased Hepatobiliary and Fecal Cholesterol Excretion upon Activation of the Liver X Receptor Is Independent of ABCA1* , 2002, The Journal of Biological Chemistry.

[42]  Pierre Apkarian,et al.  Self-scheduled H∞ control of linear parameter-varying systems: a design example , 1995, Autom..

[43]  Peter A. J. Hilbers,et al.  A Bayesian approach to targeted experiment design , 2012, Bioinform..

[44]  E. Gilles,et al.  Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors , 2002, Nature Biotechnology.

[45]  S Waldherr,et al.  Parameter identification, experimental design and model falsification for biological network models using semidefinite programming. , 2010, IET systems biology.

[46]  Jason Wittenberg,et al.  Clarify: Software for Interpreting and Presenting Statistical Results , 2003 .

[47]  Albert K Groen,et al.  The liver X receptor: control of cellular lipid homeostasis and beyond Implications for drug design. , 2010, Progress in lipid research.

[48]  Peter A. J. Hilbers,et al.  Parameter adaptations during phenotype transitions in progressive diseases , 2011, BMC Systems Biology.

[49]  Natal A. W. van Riel,et al.  Dynamic modelling and analysis of biochemical networks: mechanism-based models and model-based experiments , 2006, Briefings Bioinform..

[50]  N. V. van Riel.  Dynamic modelling and analysis of biochemical networks: mechanism-based models and model-based experiments. , 2006, Briefings in bioinformatics.

[51]  Peter Tontonoz,et al.  Reciprocal regulation of inflammation and lipid metabolism by liver X receptors , 2003, Nature Medicine.

[52]  A. Grefhorst,et al.  Pharmacological LXR activation reduces presence of SR-B1 in liver membranes contributing to LXR-mediated induction of HDL-cholesterol. , 2012, Atherosclerosis.

[53]  David J. Klinke,et al.  An empirical Bayesian approach for model-based inference of cellular signaling networks , 2009, BMC Bioinformatics.

[54]  Paul D. W. Kirk,et al.  Gaussian process regression bootstrapping: exploring the effects of uncertainty in time course data , 2009, Bioinform..

[55]  Kenneth R Feingold,et al.  Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. , 2004, Journal of lipid research.

[56]  David Hinkley,et al.  Bootstrap Methods: Another Look at the Jackknife , 2008 .

[57]  Jaques Reifman,et al.  Modeling Phenotypic Metabolic Adaptations of Mycobacterium tuberculosis H37Rv under Hypoxia , 2012, PLoS Comput. Biol..

[58]  Peter Tontonoz,et al.  Liver X Receptor Signaling Pathways and Atherosclerosis , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[59]  Klaas Nicolay,et al.  Silencing of glycolysis in muscle: experimental observation and numerical analysis , 2010, Experimental Physiology.

[60]  E. S. Pearson.  Biometrika tables for statisticians , 1967 .

[61]  A. Grefhorst,et al.  Reduced insulin-mediated inhibition of VLDL secretion upon pharmacological activation of the liver X receptor in mice This work was supported by a grant from the Ter Meulen Fund, Royal Netherlands Academy of Arts and Science, The Netherlands. , 2009, Journal of Lipid Research.

[62]  Xiangdong Wang,et al.  Clinical bioinformatics: a new emerging science , 2011, Journal of Clinical Bioinformatics.

[63]  Christopher R. Myers,et al.  Universally Sloppy Parameter Sensitivities in Systems Biology Models , 2007, PLoS Comput. Biol..

[64]  Peter A. J. Hilbers,et al.  An integrated strategy for prediction uncertainty analysis , 2012, Bioinform..

[65]  G. Wahba.  Smoothing noisy data with spline functions , 1975 .

[66]  Aleksander S. Popel,et al.  A compartment model of VEGF distribution in blood, healthy and diseased tissues , 2008, BMC Systems Biology.

[67]  Jens Timmer,et al.  Systems-level interactions between insulin–EGF networks amplify mitogenic signaling , 2009, Molecular systems biology.

[68]  E. Tse,et al.  Optimal minimal-order observer-estimators for discrete linear time-varying systems , 1970 .

[69]  Klaas Nicolay,et al.  Magnitude and control of mitochondrial sensitivity to ADP. , 2009, American journal of physiology. Endocrinology and metabolism.

[70]  N A W van Riel,et al.  Parameter uncertainty in biochemical models described by ordinary differential equations. , 2013, Mathematical biosciences.

[71]  G. Stephanopoulos,et al.  Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. , 2008, Cell metabolism.

[72]  Daniël B. van Schalkwijk,et al.  Diagnostic markers based on a computational model of lipoprotein metabolism , 2011, Journal of Clinical Bioinformatics.

[73]  B. Efron,et al.  Bootstrap confidence intervals , 1996 .

[74]  Albert Compte,et al.  Workflow for generating competing hypothesis from models with parameter uncertainty , 2011, Interface Focus.

[75]  Peter Craven,et al.  Smoothing noisy data with spline functions , 1978 .

[76]  G. Hornberger,et al.  Approach to the preliminary analysis of environmental systems , 1981 .

[77]  D. Mangelsdorf,et al.  The liver X receptor gene team: Potential new players in atherosclerosis , 2002, Nature Medicine.

[78]  Ursula Klingmüller,et al.  Theoretical and experimental analysis links isoform- specific ERK signalling to cell fate decisions , 2009, Molecular systems biology.